Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549314 · ClinicalTrials.gov registry record
Cystic Fibrosis Related Bone Disease: the Role of CFTR
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 79
- Enrollment target
NCT01549314: Completed study, sponsored by Massachusetts General Hospital.
NCT01549314 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01549314 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis with at least one G551D CFTR mutation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-04 |
| Est. Completion | 2020-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01549314
The ClinicalTrials.gov registry entry for NCT01549314 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01549314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01549314 about?
NCT01549314 is a clinical study titled "Cystic Fibrosis Related Bone Disease: the Role of CFTR". The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis with at least one G551D CFTR mutation.
What is the current status of trial NCT01549314?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2012-04. Estimated completion is 2020-02.
Who is sponsoring clinical trial NCT01549314?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.